PMOS vs PCOS — What Changed and What Didn't
What changed: the name and the conceptual framing.
What didn't change: the condition itself, the diagnostic criteria, and the treatment options. If you were diagnosed with PCOS, you now have PMOS — same condition, better name.
Breaking down PMOS letter by letter
Multiple systems affected — not just the ovaries. Reproductive, metabolic, hormonal, dermatological, and psychological systems are all involved.
The metabolic component is now front and centre. A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms including hyperandrogenism and ovulatory dysfunction. This is the core of the condition.
The ovaries are involved — but as a consequence, not the cause. The follicles seen on ultrasound are not pathological cysts — they are immature follicles that failed to develop because the hormonal environment prevented ovulation.
A collection of signs and symptoms that occur together — not a single disease with a single cause. Different women present differently, and treatment must be individualised.
Why "Polycystic" was always wrong
Doctors and researchers had argued for decades that PCOS placed too much emphasis on ovarian cysts, even though many patients diagnosed with the condition do not actually have cysts. What appear as "cysts" are actually immature follicles — arrested eggs that failed to develop because of hormonal dysfunction. Calling them cysts suggested a structural problem that wasn't really there.
The consequence of the wrong name: the reliance on the "polycystic" label contributed to misunderstanding and, in some cases, delayed diagnosis — because doctors looked for cysts and dismissed patients who didn't have them.
At Gini, Dr. Bhansali and Dr. Deepika Gupta have treated PMOS as a metabolic condition for years — testing fasting insulin, HOMA-IR, and androgen levels alongside the ultrasound. The new name finally matches the clinical reality we already practice.
Why Do Medical Conditions Get Renamed? PMOS, MASH, and More
Medical names are not just labels. They shape how doctors think about a condition, what tests they order, and what treatment they reach for first. When a name is wrong, it misdirects medicine at scale — for millions of patients, for decades. Name changes happen when the scientific understanding of a condition fundamentally shifts.
This pattern is more common than most patients realise — and it always follows the same shape: a descriptive name based on what doctors could observe, replaced by a mechanism-based name reflecting what is actually happening.
NAFLD → MASLD → MASH
Non-Alcoholic Fatty Liver Disease became Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in 2023, with the severe form called MASH (Metabolic-Associated Steatohepatitis). Why? Because "non-alcoholic" defined the disease by what it wasn't, rather than what it was — a metabolic condition driven by insulin resistance, obesity, and diet. The old name stigmatised patients who didn't drink (why do I have a liver disease associated with alcohol?) and confused doctors who focused on ruling out alcohol rather than treating the metabolic cause. Dr. Bhansali manages MASLD/MASH in many of his diabetic patients — the liver and metabolism are deeply connected.
Type 2 Diabetes → from "Adult-Onset Diabetes"
For decades, Type 2 diabetes was called Adult-Onset Diabetes. Then children started developing it — driven by the obesity epidemic. The name had to change because it was factually wrong and gave parents and doctors a false sense of security about young patients.
Heart Attack → from "Coronary Thrombosis"
The terminology for heart attacks evolved as understanding of the mechanism evolved — from "coronary thrombosis" (blood clot) to "myocardial infarction" (muscle death) to now distinguishing STEMI, NSTEMI, and ACS based on ECG and biomarker patterns. Each rename reflected better understanding and guided better treatment.
Why this matters for PMOS specifically
The renaming includes updates to clinical guidelines, medical education, and international disease classification systems — ensuring the new terminology is adopted consistently worldwide. This is not just an academic exercise. The WHO estimates that up to 70% of women with the condition may not even know they have it. A more accurate name — one that centres metabolism and hormones, not ovarian cysts — will change how GPs screen for it and how women understand their own symptoms.
Why PMOS Is Especially Important in India
PMOS affects an estimated 170 million women worldwide — and India carries a disproportionate share of this burden. Yet PMOS in Indian women presents differently from the Western textbook description, and that difference has caused decades of misdiagnosis.
Insulin resistance is more common in Indians at lower weight
Indians develop metabolic syndrome at lower BMI than Western populations. A woman with BMI 24 in India may have the same insulin resistance as a BMI 30 woman in Europe. This means PMOS can develop and progress in Indian women who appear to be at "normal" weight — and who are therefore missed entirely by doctors who use weight as a screening shortcut.
Vegetarian diets and PMOS
Many Indian women follow vegetarian diets that, if not carefully planned, are high in refined carbohydrates (rice, chapati, dal with rice) and low in protein — exactly the dietary pattern that worsens insulin resistance. This is not about vegetarianism being harmful — it's about the specific dietary patterns common in India that quietly fuel insulin resistance over years.
Stigma around "cysts"
Many Indian families treated a PCOS diagnosis as a reproductive problem, a fertility issue, something shameful or hidden. The word "polycystic" fed this stigma. PMOS — emphasising metabolism and hormones — destigmatises the condition. It is a metabolic disorder, like diabetes or thyroid disease. It can and should be discussed openly and treated systematically.
The misdiagnosis problem
Because Indian GPs often relied on the ultrasound finding of "polycystic ovaries" to diagnose PCOS, women without cysts on ultrasound were sent away without a diagnosis — despite having all the metabolic and hormonal features. PMOS criteria do not require cysts. A woman with irregular periods, elevated androgens (acne, hirsutism, hair thinning), and insulin resistance has PMOS — whether or not her ovaries show follicles on ultrasound.
I Have PCOS — Does the Rename Change My Treatment?
Direct, reassuring answer: No — and yes.
What doesn't change
Your diagnosis stands. You don't need to be re-diagnosed. The diagnostic criteria remain the same. The medications that worked before still work. Your prescriptions, your medical records, your previous test results — all of it remains valid.
What should change (if it hasn't already)
The name change should prompt every woman with PCOS/PMOS and every doctor treating her to ask one question: Are we treating the metabolic root, or just managing the symptoms?
- Birth control pill to regulate periods — symptoms suppressed, root cause untreated
- Clomiphene to induce ovulation only when trying to conceive — fertility addressed, metabolic risk ignored
- No metabolic blood work (fasting insulin, HOMA-IR, HbA1c) at any point
- No discussion of diet, exercise, or long-term diabetes/cardiovascular risk
- Fasting insulin and HOMA-IR testing
- Metformin or (in selected cases) GLP-1 therapy for insulin resistance
- Dietary intervention targeting insulin response — not just generic "eat healthy" advice
- Annual monitoring of diabetes risk, lipids, blood pressure
- AMH and full hormone panel (LH, FSH, testosterone, DHEAS, prolactin)
If you're being managed with the second list, you are being treated for PMOS — even if it was called PCOS until yesterday.
The Gini PMOS Programme
Dr. Deepika Gupta and Dr. Bhansali have always treated this condition as a metabolic-endocrine syndrome. Our protocol: full hormone panel (AMH, testosterone, DHEAS, prolactin, LH, FSH) + full metabolic panel (fasting insulin, HOMA-IR, HbA1c, lipid profile) + dietary assessment + treatment targeting the root cause. 70% of our patients conceive naturally within 6 months without IVF — because we treat the insulin resistance that was preventing ovulation. Read the full PCOS / PMOS conception protocol →
PMOS, MASH, and the Pattern of Medical Renaming — What Patients Should Know
Both renames — PCOS → PMOS and NAFLD → MASLD/MASH — share a common thread: moving from descriptive labels based on what doctors could see (cysts, fatty liver) to names that reflect the underlying mechanism (metabolic, endocrine dysfunction).
The pattern, in both cases:
| Aspect | PCOS → PMOS | NAFLD → MASH/MASLD |
|---|---|---|
| Old name described | What ultrasound showed ("cysts") | What pathology showed ("fat in the liver") |
| New name reflects | Metabolic/endocrine mechanism | Metabolic dysfunction mechanism |
| Stigma carried | "Fertility problem", "cyst disease" | "You drink too much" |
| Misdirected treatment | Ovary-focused, symptom suppression | Alcohol exclusion, no metabolic management |
| Year of rename | 2026 | 2023 |
| Underlying common driver | Insulin resistance | Insulin resistance |
It is no coincidence that both renames center insulin resistance and metabolic dysfunction. Modern medicine is recognising that many conditions once thought to be organ-specific are, in fact, expressions of the same underlying metabolic problem playing out in different tissues.
For patients, the lesson is: when a medical condition is renamed, it is worth asking your doctor — "Does this change how I should be managed?" Sometimes the answer is no. Sometimes, as with PMOS, the answer is: "You should have been managed differently all along — let's correct that."
Frequently Asked Questions
The official rename was published in The Lancet in May 2026 following a global consensus involving 22,000 stakeholders and 56 organisations. The transition to PMOS will happen over the next 3 years through updated clinical guidelines and medical education. Both terms will coexist during this transition period. If you search for PCOS, you will increasingly see PMOS used.
No. Your existing diagnosis stands. PCOS and PMOS describe the same condition — the name changed, not the criteria. All previous test results, diagnoses, and prescriptions remain valid. You do not need new tests just because of the rename.
Polyendocrine Metabolic Ovarian Syndrome.
- Poly = multiple systems affected
- Endocrine = hormonal system involvement
- Metabolic = metabolic disruption (insulin resistance) at the core
- Ovarian = ovarian involvement (though not the cause)
- Syndrome = collection of features occurring together
The old name was a misnomer. "Polycystic" suggested the condition was defined by ovarian cysts — but many patients don't have cysts, and the cysts that do appear are actually immature follicles caused by hormonal disruption, not the cause of it. The name focused treatment on the ovaries when the real condition is metabolic and hormonal. The result was decades of under-diagnosis (in women without visible cysts) and mis-treatment (focused on the ovaries rather than insulin resistance).
The condition and its treatments haven't changed. What should change is emphasis — treatment should focus on the metabolic root (insulin resistance) rather than just managing symptoms like irregular periods or fertility issues. If your current treatment is only birth control or ovulation induction without addressing insulin resistance, discuss the PMOS framework with your doctor.
Both renames reflect the same pattern — moving from a description of what doctors could see (cysts, fat in the liver) to a name that reflects the underlying metabolic mechanism. Both renames are intended to improve clinical thinking and remove stigma. They reflect a broader trend in medicine towards mechanism-based naming. Both, notably, identify insulin resistance and metabolic dysfunction as the underlying driver.
Beyond the standard ultrasound and period history:
- Fasting Insulin
- HOMA-IR (insulin resistance index)
- HbA1c
- AMH (Anti-Müllerian Hormone)
- Full hormone panel: LH, FSH, Testosterone, DHEAS, Prolactin
- Lipid Profile
- Thyroid (TSH, free T4)
This is the full metabolic-hormonal picture that the PMOS name now demands. At Gini, this is our standard PMOS workup from the first appointment — not added later if symptoms persist.
PMOS can be very effectively managed and in many cases its symptoms can be fully resolved — particularly when insulin resistance is treated early. Many patients achieve regular cycles, natural conception, and normal hormone levels with proper metabolic treatment. "Cure" depends on definition — the underlying endocrine predisposition remains, but symptoms and health risks can be normalised. Lifelong metabolic monitoring is still recommended even after symptoms resolve.